Immunomedics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Immunomedics Inc (IMMU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Immunomedics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-28.2% annualized vs trailing 12 months).
- Peer revenue share: Immunomedics Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IMMU Sales vs. its Competitors, Q2 2018
Immunomedics Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 3.0% year over year, combined, vs -39.7% for Immunomedics Inc. Immunomedics Inc's share of combined industry revenue moved from 0.02% to 0.01%, a loss of 0.01 percentage points.
Immunomedics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Immunomedics Inc | - | - | - | No |
| High-Confidence Competitors (61) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IMMU Stock Performance relative to its Competitors
IMMU Stock Performance relative to High-Confidence Competitors
Immunomedics Inc's Competitors Named by the Company
Competitive relationships identified from Immunomedics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Autolus Therapeutics Plc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Aptevo Therapeutics Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Tevogen Bio Holdings Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Alfasigma S.p.A. | Company report | 85% |
| ENTO | Company report | 85% |
| Eiger Biopharmaceuticals Inc | Company report | 85% |
| Intercept Pharmaceuticals | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Agenus Inc | Company report | 85% |
| Assembly Biosciences Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| PHGEU | Company report | 85% |
| Genfit S a | Company report | 85% |
| Jasper Therapeutics Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Biomx Inc | Company report | 85% |
| GLTO | Company report | 85% |
| Damora Therapeutics Inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| RENB | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| Senti Biosciences Holdings Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Phoenix Biotech Acquisition Corp | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Cocrystal Pharma Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Vir Biotechnology Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Sanofi | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Chimerix Inc | Company report | 85% |
| Sorrento Therapeutics Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Viking Therapeutics Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Iteos Therapeutics Inc | Company report | 85% |
| Atara Biotherapeutics Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Aligos Therapeutics Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Argenx Se | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Atea Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Immunomedics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.